ASLAN Pharmaceuticals Limited (ASLN)

0,4244 -0,0227 (-5,08%) Börsenschluss: 04:00PM EDT

ASLAN Pharmaceuticals Limited

3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
Singapore
65 6817 9598
https://aslanpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 35

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.	Founder, CEO & Executive Director	N/A	N/A	1973
Mr. Kiran Kumar Asarpota	COO & Head of Finance	N/A	N/A	1979
Mr. Ben Goodger	General Counsel	N/A	N/A	1963
Mr. Stephen Doyle	Chief Business Officer	N/A	N/A	1973
Dr. Alexandre Kaoukhov M.D.	Chief Medical Officer	N/A	N/A	1974
Charlie Hsu	Investor Relations Director	N/A	N/A	N/A
Chi-Chin Wang	IR & Corporate Development Director	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Corporate Governance

ASLAN Pharmaceuticals Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.